Survodutide now has published Phase 3 human evidence showing meaningful weight loss, alongside late-stage liver-disease research. It remains investigational, so positive trial results are not the same as regulatory approval.
Still uncertain: Long-term cardiovascular benefit and safety, durable liver outcomes and the final benefit-risk profile required for routine use.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
SYNCHRONIZE-1 showed significant body-weight reduction in adults with obesity without diabetes. SYNCHRONIZE-MASLD showed large MRI-assessed liver-fat reductions and weight loss in adults with obesity and at-risk MASLD.
Regulatory status
Investigational; no general marketing authorisation for obesity or MASLD identified in the reviewed jurisdictions.
Main limitations
Long-term cardiovascular safety/benefit, durable MASH outcomes and routine-use dosing remain under Phase 3 investigation.
Safety
GI effects are common; long-term and rare-event safety is not yet established.
Evidence reviewed
2026-09-20
i
Published Phase 3 SYNCHRONIZE-1 evidence now shows significant weight loss in adults with obesity, alongside late-stage MASLD/MASH evidence. Survodutide remains investigational.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Using the efficacy estimand, 84.2% of survodutide participants versus 24.3% with placebo achieved at least 30% liver-fat reduction; mean body-weight change was -12.2% versus -1.0%.
At week 76, mean body-weight change was -12.2% with 3.6 mg and -13.0% with 6.0 mg versus -5.4% with placebo; 72.6%, 71.9% and 46.3%, respectively, achieved at least 5% weight reduction.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
4structured study records
2outcome records
6linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
